Series A Funded Biotechnology Startups
The 50 entries on this page cover Series A rounds closed between February and November 2025, with disclosed amounts ranging from $1M (CorriXR Therapeutics,…
The 50 entries on this page cover Series A rounds closed between February and November 2025, with disclosed amounts ranging from $1M (CorriXR Therapeutics, Wilmington) to $187M (Callio Therapeutics, Seattle). US-headquartered companies account for the majority of entries, with Boston, the San Francisco Bay Area, and San Diego each appearing multiple times. The heaviest concentration of deal activity falls in September through November 2025, a stretch that includes Reunion Neuroscience's $133M close in Toronto and Curve Biosciences' $40M raise in Mountain View.
Beyond North America, Paris produced three rounds — EVerZom, Genomines, and One Biosciences — and Lausanne generated two $65M raises in a single month, with ReproNovo and HAYA Therapeutics both closing in May 2025. Entries also include companies from Melbourne, Oslo, Leuven, Vilnius, and Bengaluru, reflecting a wide geographic distribution of Series A biotech capital. Five rounds, including all three Chinese entries, carry undisclosed amounts.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed Series A rounds in this set?
Callio Therapeutics (Seattle) leads at $187M, closed March 2025, followed by Reunion Neuroscience (Toronto) at $133M in September 2025 and Nudge (San Francisco) at $100M in July 2025. Augustine Therapeutics (Leuven, Belgium) raised $84M in March and Actithera (Oslo) closed $76M in July, both among the largest non-US entries.
Which US cities are most active for Series A biotech deals in this data?
The San Francisco Bay Area — including San Francisco, South San Francisco, Mountain View, and Palo Alto — accounts for the most individual entries, with Boston and San Diego each contributing several rounds. Austin appears twice with Phantom Neuro and QbDVision, both closing in 2025.
Are there notable non-US hubs for Series A biotech represented here?
Paris is the most active non-US city, with three rounds: EVerZom ($12M), Genomines ($45M), and One Biosciences ($17M). Lausanne stands out for density — ReproNovo and HAYA Therapeutics each closed $65M rounds in May 2025. Toronto, London, and Lausanne each contributed two entries.
How many of these rounds have undisclosed amounts?
Five of the 50 rounds list undisclosed amounts: JGene Biotechnology (Shenzhen), U-Sweet Biotechnology (Changzhou), Bambusa Therapeutics (Boston), Taihao Biotechnology (Beijing), and Certify Health (Gaithersburg). Three of the five are China-based companies.
What does the round size distribution look like across the 50 entries?
Among the 45 rounds with disclosed amounts, sizes range from $1M (CorriXR Therapeutics, Wilmington) to $187M (Callio Therapeutics, Seattle), with a median around $21M. PACT (Cambridge, UK), Parallel Bio (Watertown), and Inceptor Bio (Raleigh) all closed at exactly $21M, illustrating how clustered mid-range deals are.
What date range do these 50 entries cover?
The most recent entry is immunitoAI's $6M round in Bengaluru on November 29, 2025; the oldest is Atrandi Biosciences (Vilnius) from February 18, 2025. The heaviest concentration of activity falls in the September–November 2025 window, which accounts for 11 of the 50 rounds shown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.